Alizapride

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Antiemetic, dopamine antagonist.

Indication
This section has been translated automatically.

Prophylactically for cytostatic-induced vomiting, radiation damage or post-operatively.

Limited indication
This section has been translated automatically.

Pregnancy, renal insufficiency.

Dosage and method of use
This section has been translated automatically.

For cytostatic drug therapy 150 mg p.o. before and 150 mg after cytostasis, 3 times 50 mg p.o. the following day. Alternatively 100 mg i.v. before and 100 mg i.v. or i.m. after cytostatic drug application.

Undesirable effects
This section has been translated automatically.

CNS disorders, dizziness, RR decline, diarrhea, dry mouth, amenorrhea.

Interactions
This section has been translated automatically.

Table 1.

Contraindication
This section has been translated automatically.

Children < 14 years, pheochromocytoma, late dyskinesia, prolactinoma.

Preparations
This section has been translated automatically.

Vergentan

Tables
This section has been translated automatically.

Key interactions of alizapride

Alimemazine

extrapyramidal symptoms ↑

Anticholinergics

mutual effect ↓

Alcohol

central attenuation

Chlorphenethazine

extrapyramidal symptoms ↑

Lisurid

Lisuride effect ↓

Mequitazine

extrapyramidal symptoms ↑

Neuroleptics

extrapyramidal symptoms ↑, avoid combination

Scopolamine

Scopolamine effect ↓

CNS damping agent

central damping ↑

Authors

Last updated on: 29.10.2020